Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

224 results
Display

Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

Yoo J, Cho H, Lee DH, Cho EJ, Joo I, Jeon SK

Background/Aims: The prediction of clinical outcomes in patients with chronic hepatitis B (CHB) is paramount for effective management. This study aimed to evaluate the prognostic value of computed tomography (CT)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”

Emiroglu HH

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Lin CL, Kao JH

Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

Cho Y, Kim BH, Park JW

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Yoo JJ, Kim SG

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chu CM, Liaw YF

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The role of different viral biomarkers on the management of chronic hepatitis B

Mak LY, Hui RWH, Fung J, Seto WK, Yuen MF

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors

Lan MY, Lin HCL, Hu TH, Chen SFC, Chen CH, Chang YY, Chiu KW, Lin TK, Chen SS

Background and Purpose Oral nucleos(t)ide analogs (NAs) are the mainstay treatment for chronic hepatitis B (CHB). Myotoxicity is an important extrahepatic effect related to NA treatment. Telbivudine is the NA...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Mak LY, Wong D, Kuchta A, Hilfiker M, Hamilton A, Chow N, Mao X, Seto WK, Yuen MF

Background/Aims: We investigated the dynamics of serum HBV pre-genomic RNA (pgRNA) and hepatitis B core-related antigen (HBcrAg) in patients receiving nucleos(t)ide analogues (NAs) and their predictability for favourable suppression of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis

Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, Yuen MF

Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Yu JH, Cho SG, Jin YJ, Lee JW

Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines for management of chronic hepatitis B

The Korean Association for the Study of the Liver (KASL)

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Jeong J, Shin JW, Jung SW, Park EJ, Park NH

Background/Aims: Tenofovir alafenamide (TAF) has shown less favorable effect on lipids compared to tenofovir disoproxil fumarate (TDF) in clinical trials. However, data regarding these outcomes in patients with chronic hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of superb microvascular imaging and shear wave elastography for assessing liver fibrosis in chronic hepatitis B

Tosun M, Uslu H

Purpose: The present study investigated the effectiveness and applicability of superb microvascular imaging (SMI) in determining the degree of liver fibrosis noninvasively in comparison with shear wave elastography (SWE). Methods: Ninety-eight...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database

Choe JW, Jung YK, Yim HJ, Seo GH

Background: Several studies have recently suggested that liver disease and cirrhosis were risk factors for poor outcomes in patients with coronavirus disease 2019 (COVID-19) infections. However, no large data study has...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Tamaki N, Kurosaki M, Loomba R, Izumi N

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma

Mak LY, Ko KL, To WP, Wong DKH, Seto WK, Fung J, Yuen MF

Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?

Jang BK

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B

Kim GA, Shim JJ, Lee JS, Kim BH, Kim JW, Oh CH, Oh CM, Oh IH, Park SY

Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr